ANDA 76287, held by Ani Pharms. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 76287 (Fluoxetine Hydrochloride), held by Ani Pharms, was first approved by FDA on May 20, 2008, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2008 | Original application | Approved |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Aug 18, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 5, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 31, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 22, 2010 | Supplement 5Labeling | Approved | None posted |
| Jul 14, 2009 | Supplement 3Labeling | Approved | None posted |
| Jan 26, 2009 | Supplement 2Labeling | Approved | None posted |
| May 20, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters